Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tinlarebant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Belite Brings FDA Filing Into View with Phase 3 Stargardt Win
    Belite Brings FDA Filing Into View with Phase 3 Stargardt Win

    01 Dec 2025

    // PRESS RELEASE

    https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite

    PRESS RELEASE
    01 Dec 2025
    Share Share
    Belite Bio Reports Q3 2025 Financial Results & Corporate Update
    Belite Bio Reports Q3 2025 Financial Results & Corporate Update

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184490/0/en/Belite-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Belite Bio Gets Conditional UK Approval For Tinlarebant
    Belite Bio Gets Conditional UK Approval For Tinlarebant

    02 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/02/3178795/0/en/Belite-Bio-Announces-UK-s-Medicines-and-Healthcare-Products-Regulatory-Agency-Agrees-to-Conditional-Marketing-Authorization-Application-Based-on-Interim-Analysis-Results-for-the-Tr.html

    GLOBENEWSWIRE
    02 Nov 2025
    Share Share
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167044/0/en/Belite-Bio-Announces-China-NMPA-Agrees-to-New-Drug-Application-with-Priority-Review-based-on-Interim-Analysis-Results-for-the-Treatment-of-Stargardt-Disease-with-Tinlarebant.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease

    12 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/12/3149167/0/en/Belite-Bio-Announces-Completion-of-DRAGON-a-2-Year-Phase-3-Trial-of-Oral-Tinlarebant-in-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    12 Sep 2025
    Share Share
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3108920/0/en/Belite-Bio-Announces-Completion-of-Enrollment-in-the-Pivotal-Global-Phase-3-PHOENIX-Trial-Evaluating-Oral-Tinlarebant-in-Geographic-Atrophy.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share